Accera
Navigation Links
Accera in Medical News
Experimental Drug Ketasyn(TM) (AC-1202) Treats Alzheimer's as Diabetes of the Brain
...n often appear 10 to 20 years earlier than other AD symptoms, targeting them may allow for earlier treatment of the disease. Based on this hypothesis, accera is developing the AD drug, Ketasyn(TM) (AC-1202), which provides glucose-deprived brain cells with an alternative energy source. Ketasyn is converted ...A Milky Alternative to Alzheimer Drug
...togenic diet sometimes used for children with severe epilepsy. Manufacturer accera is currently hunting funding for a Phase III study, and exploring different...ned Dr. Lauren Constantini, a former Harvard scientist now with the company accera Inc. that is developing the drug. To stop Alzheimer's brain decay,...Accera in Medical Technology
Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
...w and similar between Ketasyn and placebo groups. accera recently completed a Phase IIb clinical trial in A...e for efficacy in cognition and short-term memory. accera plans to initiate a pivotal, Phase III multi-cente...r's disease and Age- Associated Memory Impairment. accera has other small molecule compounds in its product ...... BROOMFIELD, Colo., April 24, 2007 /PRNewswire/ -- accera Inc. announced today that topline data from its Phase IIb study of its lead compound AC-1202 in Alzheimer's disease (AD) will be presented at the annu...
... BROOMFIELD, Colo., May 01, 2007 /PRNewswire/ -- accera Inc. is presenting topline data today from its Phase IIb study of its lead compound AC-1202 in Alzheimer's disease (AD) at the American Academy of Neu...
Accera in Biological Technology
BROOMFIELD, Colo., March 2 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, today launched Axona(TM) in the United States for Alzheimer's disease (AD). Axona is a first-in-class medical food for the clinical dietary...
Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease
...ona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer's disease. accera engages in research, development and commercialization of other clinical applications for Axona. For more information about Accera, please v...Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
... a wholly owned subsidiary and will be spun out of accera as a stand-alone company after the completion of a $12 million series A financing round. Existing accera investors have already committed to participate in...ompany, and the current small molecule pipeline at accera including the preclinical compounds, AC-0523 and A...Accera, Inc. to Present at Upcoming Investor Conferences
...d-to-moderate Alzheimer's disease. Dr. Orndorff will provide an overview of accera and its technology pipeline and also provide an update on the successful na...ve, well-tolerated treatments. Through its proprietary scientific platform, accera is developing therapies that address metabolic deficiencies by providing an...Dr. Thomas Werner Elected to Accera, Inc.'s Board of Directors
... impact patients with neurodegenerative disorders who are in need of effective, well-tolerated therapies. Through its proprietary scientific platform, accera is developing products that address metabolic deficiencies associated with certain neurodegenerative diseases by providing an alternative energy sourc...Accera, Inc. Sponsors Alzheimer's Association's 2009 ICAD Conference
...f, Ph.D., Accera's founder and CEO. "As a company focused on CNS disorders, accera is committed to improving the care and quality of life of Alzheimer's patie...ive, well-tolerated therapies. Through its proprietary scientific platform, accera is developing products that address metabolic deficiencies associated with ...Accera, Inc. Completes $35 Million Series C Financing
...estament to the confidence of our investors in the accera organization and the potential of Axona". Wolfga... a new approach to neurodegenerative diseases, and accera is a clear leader. We are pleased to support the c...pies. Through its proprietary scientific platform, accera is developing products that address metabolic defi...Accera, Inc. Names William T. Poncy Vice President of Commercial Development
... BROOMFIELD, Colo., Oct. 10 /PRNewswire/ -- accera Inc., a privately held biotechnology company focus...Ketasyn's excellent safety and efficacy will allow accera to make a competitive entry into the multi billion... (AD) and age-associated memory impairment (AAMI). accera plans to self-commercialize Ketasyn as a medical f...Accera, Inc. to Present at the 4th Annual BIO Investor Forum
... BROOMFIELD, Colo., Oct. 4 /PRNewswire/ -- accera Inc., a privately held biotechnology company focused on developing novel dr... October 11 at 11:00 a.m. PDT. Dr. Orndorff will provide an overview of accera and its technology platform as well as a summary of the positive data from ...Other TagsRemoveOther Contentsovulesovumovumovumovumoxidationoxidationoxidationoxidationoxidationoxidationoxygenoxygenoxygenoxygenoxygenoxygenoxygenoxygenoxygenoxygenatedoxygenatedoxygenatedelementselementselementselementselementselementselementselementselementspachytene
RemoveCatastrophicDoxycyclineMentholMalayaliDubaiConsistentAbolishDoomedNonsteroidalTallerGeorgetownDeliberationCompost
(Date:11/27/2009)...7 Shamir Optical Industr...ovider of innovative products and technology to th... board of directors had declared a dividend distri...pproximately NIS 37.62 million based on the Novemb...pproximately US$ 0.609 (approximately NIS 2.3 base...
(Date:11/27/2009)...rade; announced today that Spectrum Health (Grand ...prise orthopedic templating solution and its Traum... (PRWEB) November 27, 2009 -- Voyant Health...d Rapids, Michigan) has licensed its TraumaCad Ent...umaCad Extend workflow solution, to allow its orth...
(Date:11/26/2009)...RNewswire/ -- The diabetes population in the Unite... and annual medical spending on the disease is pro...oday, according to a study published in the Decemb...ng Diabetes ® Program (NCDP), a program of No...om the University of Chicago. ,, According to t...
(Date:11/26/2009)... from the North Pole, Textsanta.net lets parents s..., North Pole, AK (PRWEB) -...s at the North Pole Santa Claus has added SMS text...e informed of his Christmas progress at the North ...nt have identified a large and growing percentage ...
(Date:11/25/2009)...wire-USNewswire/ -- When most people hear the acro...practor can also give patients the help they need....ch is where your jaw (mandible) contacts/connects ...ommon symptoms associated with TMJ dysfunction are.... But many other symptoms can be caused from TMJ ...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2[0] Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend[0] Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend[1] Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows[1] Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes[1] TMJ and Chiropractic Care: An Overall Wellness Approach
(Date:11/23/2009).... November 23, 2009 Applied mathematicians disse...ancifolia ), a characteristic long leaf with a sad... along the edges. The simple cause of the lily,s f...ding during differential growthwas revealed by usi...bbons. , Haiyi Liang, a postdoctoral student at ...
(Date:11/23/2009)...e Wildlife Conservation Society says that western ...public of Congopart of the "mother lode" of more t...ing increasingly threatened by growing humans acti...ction of the swamp forests adjacent to the southwe... surveys confirmed that high densities of the grea...
(Date:11/23/2009)...rent research suggests that a common oral bacteriu...report by Nichols et al, "Unique Lipids from a Com...Ligands Capable of Enhancing Autoimmunity," appear...nal of Pathology . , Multiple sclerosis (MS), a ...and spinal cord, affects nearly 1 in 700 people in...
Breaking Biology News(10 mins):The cause behind the characteristic shape of a long leaf revealed 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Factors from common human bacteria may trigger multiple sclerosis 2Arcadia Resources Announces Closing of 2411 1 Million Financing 61915 1Arcadia Resources Announces Closing of 2411 1 Million Financing 61915 2Inimex Announces Appointment of New CEO 14941 1Inimex Announces Appointment of New CEO 14941 2Pearl Therapeutics Appoints Howie Rosen to Board of Directors 14939 1Pearl Therapeutics Appoints Howie Rosen to Board of Directors 14939 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |